These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 19896358)

  • 1. Optimization of Fc-mediated effector functions of monoclonal antibodies.
    Strohl WR
    Curr Opin Biotechnol; 2009 Dec; 20(6):685-91. PubMed ID: 19896358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology.
    Huang C
    Curr Opin Biotechnol; 2009 Dec; 20(6):692-9. PubMed ID: 19889530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies.
    Davis JH; Aperlo C; Li Y; Kurosawa E; Lan Y; Lo KM; Huston JS
    Protein Eng Des Sel; 2010 Apr; 23(4):195-202. PubMed ID: 20299542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of humanized antibodies: from anti-Tac to Zenapax.
    Tsurushita N; Hinton PR; Kumar S
    Methods; 2005 May; 36(1):69-83. PubMed ID: 15848076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fc engineering: design, expression, and functional characterization of antibody variants with improved effector function.
    Derer S; Kellner C; Berger S; Valerius T; Peipp M
    Methods Mol Biol; 2012; 907():519-36. PubMed ID: 22907372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody therapeutics, antibody engineering, and the merits of protein stability.
    Demarest SJ; Glaser SM
    Curr Opin Drug Discov Devel; 2008 Sep; 11(5):675-87. PubMed ID: 18729019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selection, design, and engineering of therapeutic antibodies.
    Presta LG
    J Allergy Clin Immunol; 2005 Oct; 116(4):731-6; quiz 737. PubMed ID: 16210043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing the potency of therapeutic monoclonal antibodies via Fc optimization.
    Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Johnson S; Koenig S; Bonvini E
    Adv Enzyme Regul; 2008; 48():152-64. PubMed ID: 18177741
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
    Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
    Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oligomerization is required for the activity of recombinant soluble LOX-1.
    Cao W; Calabro V; Root A; Yan G; Lam K; Olland S; Sanford J; Robak A; Zollner R; Lu Z; Ait-Zahra M; Agostinelli R; Tchistiakova L; Gill D; Harnish D; Paulsen J; Shih HH
    FEBS J; 2009 Sep; 276(17):4909-20. PubMed ID: 19664054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and expression of polymeric immunoglobulin fusion proteins: a strategy for targeting low-affinity Fcgamma receptors.
    White DM; Jensen MA; Shi X; Qu Zx ; Arnason BG
    Protein Expr Purif; 2001 Apr; 21(3):446-55. PubMed ID: 11281720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Refined structure of an intact IgG2a monoclonal antibody.
    Harris LJ; Larson SB; Hasel KW; McPherson A
    Biochemistry; 1997 Feb; 36(7):1581-97. PubMed ID: 9048542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality.
    Scallon BJ; Tam SH; McCarthy SG; Cai AN; Raju TS
    Mol Immunol; 2007 Mar; 44(7):1524-34. PubMed ID: 17045339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapeutic antibodies and related products: choosing the right structure for success].
    Beck A; Wagner-Rousset E; Wurch T; Corvaia N
    Med Sci (Paris); 2009 Dec; 25(12):1024-32. PubMed ID: 20035674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic antibodies: magic bullets hit the target.
    Gura T
    Nature; 2002 Jun; 417(6889):584-6. PubMed ID: 12050630
    [No Abstract]   [Full Text] [Related]  

  • 16. Characterization of IgG1 immunoglobulins and peptide-Fc fusion proteins by limited proteolysis in conjunction with LC-MS.
    Kleemann GR; Beierle J; Nichols AC; Dillon TM; Pipes GD; Bondarenko PV
    Anal Chem; 2008 Mar; 80(6):2001-9. PubMed ID: 18293943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular engineering and design of therapeutic antibodies.
    Presta LG
    Curr Opin Immunol; 2008 Aug; 20(4):460-70. PubMed ID: 18656541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities.
    Natsume A; In M; Takamura H; Nakagawa T; Shimizu Y; Kitajima K; Wakitani M; Ohta S; Satoh M; Shitara K; Niwa R
    Cancer Res; 2008 May; 68(10):3863-72. PubMed ID: 18483271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological significance of glycosylation in therapeutic proteins.
    Li H; d'Anjou M
    Curr Opin Biotechnol; 2009 Dec; 20(6):678-84. PubMed ID: 19892545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of Fc-erythropoietin structure and pharmacokinetics by modification at a disulfide bond.
    Way JC; Lauder S; Brunkhorst B; Kong SM; Qi A; Webster G; Campbell I; McKenzie S; Lan Y; Marelli B; Nguyen LA; Degon S; Lo KM; Gillies SD
    Protein Eng Des Sel; 2005 Mar; 18(3):111-8. PubMed ID: 15820978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.